Membrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study.
Cancer diagnosis and monitoring
HSP70-exosomes
Liquid biopsy
Pilot study
Solid tumours
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
08
2019
accepted:
24
02
2020
entrez:
13
3
2020
pubmed:
13
3
2020
medline:
13
3
2020
Statut:
epublish
Résumé
Cancer is the second leading cause of death globally. Early detection and disease management lead to a better survival rate. Consequently, discovery of novel methods in cancer early diagnosis is a field of active research. Minimally invasive liquid biopsies are generating growing interest. Circulating tumour cells (CTCs) have been identified in patients' blood; nevertheless, these cells are rare and heterogeneous. Exosomes are extracellular nanovesicles released into the extracellular environment via the endosomal vesicle pathway and found in different body fluids. Exosomes deliver bioactive cargo such as proteins, mRNA and miRNA to recipient cells in the tumour environment. We have recently shown that heat shock protein 70 (HSP70) is detected in the membrane of tumour-derived exosomes, in contrast to normal cells. One single cancer cell can release thousands of HSP70-exosomes, facilitating detection. The aim of the pilot study ExoDiag is to determine whether it is possible to detect and quantify HSP70-exosomes in blood in patients with solid cancers. Bicentric pilot study that will include 60 adult patients with metastatic and non-metastatic solid tumours and 20 healthy volunteers. Exosomes will be isolated from blood and urine samples, and HSP70 concentration will be determined. Patients will be followed for 1 year. The study is sponsored by Georges-François Leclerc Centre and is currently ongoing. We expect to demonstrate that HSP70-exosomes could be a powerful tool to diagnose cancer and to guide clinicians in therapeutic decision-making, improving patient's care. ClinicalTrials.gov identifier NCT02662621. Registered 20 January 2016, https://clinicaltrials.gov/ct2/show/study/NCT02662621?term=NCT02662621&rank=1.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer is the second leading cause of death globally. Early detection and disease management lead to a better survival rate. Consequently, discovery of novel methods in cancer early diagnosis is a field of active research. Minimally invasive liquid biopsies are generating growing interest. Circulating tumour cells (CTCs) have been identified in patients' blood; nevertheless, these cells are rare and heterogeneous. Exosomes are extracellular nanovesicles released into the extracellular environment via the endosomal vesicle pathway and found in different body fluids. Exosomes deliver bioactive cargo such as proteins, mRNA and miRNA to recipient cells in the tumour environment. We have recently shown that heat shock protein 70 (HSP70) is detected in the membrane of tumour-derived exosomes, in contrast to normal cells. One single cancer cell can release thousands of HSP70-exosomes, facilitating detection. The aim of the pilot study ExoDiag is to determine whether it is possible to detect and quantify HSP70-exosomes in blood in patients with solid cancers.
METHODS
METHODS
Bicentric pilot study that will include 60 adult patients with metastatic and non-metastatic solid tumours and 20 healthy volunteers. Exosomes will be isolated from blood and urine samples, and HSP70 concentration will be determined. Patients will be followed for 1 year. The study is sponsored by Georges-François Leclerc Centre and is currently ongoing.
DISCUSSION
CONCLUSIONS
We expect to demonstrate that HSP70-exosomes could be a powerful tool to diagnose cancer and to guide clinicians in therapeutic decision-making, improving patient's care.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov identifier NCT02662621. Registered 20 January 2016, https://clinicaltrials.gov/ct2/show/study/NCT02662621?term=NCT02662621&rank=1.
Identifiants
pubmed: 32161659
doi: 10.1186/s40814-020-00577-2
pii: 577
pmc: PMC7053097
doi:
Banques de données
ClinicalTrials.gov
['NCT02662621']
Types de publication
Journal Article
Langues
eng
Pagination
35Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Natl Cancer Inst. 2015 Nov 22;108(3):
pubmed: 26598503
Br J Cancer. 2012 Jun 26;107(1):63-70
pubmed: 22627320
Cell Adh Migr. 2017 Mar 4;11(2):151-163
pubmed: 28166442
Oncogene. 2015 Oct;34(43):5460-71
pubmed: 25659585
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24
pubmed: 16857794
Carcinogenesis. 2013 Jun;34(6):1181-8
pubmed: 23563090
J Immunol. 2006 Feb 1;176(3):1534-42
pubmed: 16424182
Eur J Cancer. 2014 Mar;50(5):1025-34
pubmed: 24462375
ScientificWorldJournal. 2010 Aug 03;10:1543-52
pubmed: 20694452
Lung Cancer. 2018 Feb;116:46-54
pubmed: 29413050
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Transl Res. 2017 Jul;185:58-84.e15
pubmed: 28506696
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13368-73
pubmed: 15326289
Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794630
pubmed: 30181785
J Clin Invest. 2010 Feb;120(2):457-71
pubmed: 20093776
Cell Stress Chaperones. 2005 Summer;10(2):86-103
pubmed: 16038406
Acta Cytol. 2012;56(6):655-60
pubmed: 23207444
Methods. 2007 Nov;43(3):229-37
pubmed: 17920520
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Prion. 2007 Jan-Mar;1(1):53-60
pubmed: 19164900